Esteve Pharmaceuticals, S.a.

This study is a global registry that collects safety information from children and teenagers with severe primary IGF-1 deficiency who are taking the drug Increlex. It does not test a new treatment but instead monitors side effects and long-term outcomes for up to 5 years after tr…